Sugi Predict

Sugi Predict / Compounds / SCHEMBL6690977

SCHEMBL6690977

SCHEMBL6690977

C[C@@H](C(=O)O)N(C(=O)[C@@H](N)CC(=O)O)c1ccccc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ ALPI P09923 1/20 0.38
▸ PKM P14618 1/20 0.38
▸ PTGS1 P23219 1/20 0.38
▸ XIAP P98170 1/20 0.38
▸ SLC7A5 Q01650 1/20 0.38
▸ PGR P06401 1/20 0.37
▸ ADRA2A P08913 1/20 0.37
▸ ADRA2B P18089 1/20 0.37
▸ HTR2A P28223 1/20 0.37
▸ HRH1 P35367 1/20 0.37
▸ KCNH2 Q12809 1/20 0.37
▸ ANPEP P15144 1/20 0.37
▸ RNPEP Q9H4A4 1/20 0.37
▸ DNPEP Q9ULA0 1/20 0.37
▸ LTA4H P09960 3/20 0.36
▸ CPA1 P15085 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1434038 1.00 ALDH1A1 (0.43) ALDH1A1LMNATP53SMN1; SMN2ALPI
SCHEMBL23923952 0.86 KMT2A (0.42) ALDH1A1LMNATP53SMN1; SMN2PTGS1
SCHEMBL421787 0.86 KMT2A (0.42) ALDH1A1LMNATP53SMN1; SMN2PTGS1
SCHEMBL9514133 0.85 MEN1 (0.43) ALDH1A1LMNATP53SMN1; SMN2PGR
SCHEMBL11478785 0.84 ALDH1A1 (0.45) ALDH1A1LMNATP53SMN1; SMN2PGR
SCHEMBL10883595 0.84 ALPI (0.56) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL8681167 0.82 ALDH1A1 (0.45) ALDH1A1LMNATP53SMN1; SMN2ALPI
SCHEMBL27843438 0.82 ALDH1A1 (0.45) ALDH1A1LMNATP53SMN1; SMN2ALPI
SCHEMBL7538324 0.82 SLC1A3 (0.35) ALDH1A1PTGS1GAAL3MBTL1
SCHEMBL27282127 0.81 ALPI (0.53) ALPIPKMPTGS1XIAPSLC7A5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2004076477-A1 MICROBIOLOGICAL PRODUCTION METHOD FOR α-L-ASPARTYL-L-PHENYLALANINE HOLLAND SWEETENER COMPANY (NL) 2004-09-10 — — WO claimed
US-6384272-B2 FORMATION OF AMMONIUM SALT OF (ALPHA-ASPARTYL)PHENYLALANINE BY AMIDATION OF ESTER OF (ALPHA-ASPARTYL)PHENYLALANINE, THEN (ALPHA-ASPARTYL)-BETA-CYCLOHEXYLALANINAMIDE IS OBTAINED BY CATALYTIC HYDROGENATION AVENTIS PHARMA S.A. (FR) 2002-05-07 — — US claimed
US-20010034460-A1 Method for preparing aspartylcyclohexyla laninamide AVENTIS PHARMA S.A. (FR) 2001-10-25 — — US claimed
EP-0225684-B1 AN IMPROVED PROCESS FOR PRODUCING A RAPIDLY WATER-SOLUBLE, FREE-FLOWING, SUGAR-FREE DRY BEVERAGE MIX KRAFT GENERAL FOODS CANADA INC. (CA) 1992-08-12 — — EP claimed
EP-0220176-B1 DRAGEE AND METHOD FOR ITS MANUFACTURE Ferrero S.p.A. (IT) 1989-08-02 — — EP claimed
EP-0126570-B1 A POWDER FILLED CHEWING GUM PIECE WARNER-LAMBERT COMPANY (US) 1988-08-03 — — EP claimed
EP-0270345-A2 Preparation of alpha-L-aspartyl-L-phenyl-alanine methyl ester or hydrohalide thereof MITSUI TOATSU CHEMICALS, Inc. (JP) 1988-06-08 — — EP claimed
US-4684523-A Dragee and method for its manufacture FERRERO S.P.A. (IT) 1987-08-04 — — US claimed
EP-0225684-A1 An improved process for producing a rapidly water-soluble, free-flowing, sugar-free dry beverage mix KRAFT GENERAL FOODS CANADA INC. (CA) 1987-06-16 — — EP claimed
US-5094844-A Exzyme inhibitors, polyvinylphosphonate COLGATE-PALMOLIVE COMPANY (US) 1992-03-10 — — US disclosed
US-4929447-A POLYVINYL ACETATE, PLASTICIZERS, TIME-RELEASE AGENTS WARNER-LAMBERT COMPANY (US) 1990-05-29 — — US disclosed
US-4883888-A USED TO AMIDATE DIPEPTIDE TYPE SWEETENERS THE PROCTER & GAMBLE COMPANY (US) 1989-11-28 — — US disclosed
EP-0154472-B1 PROCESS FOR THE PRODUCTION OF L-ASPARTYL-L-PHENYLALANINE ESTER AJINOMOTO CO., INC. (JP) 1989-10-11 — — EP disclosed
EP-0220176-B1 DRAGEE AND METHOD FOR ITS MANUFACTURE Ferrero S.p.A. (IT) 1989-08-02 — — EP disclosed
EP-0030076-B1 PURIFICATION OF L-ASPARTYL-L-PHENYLALANINE ALKYL ESTERS PFIZER INC. (US) 1983-10-19 — — EP disclosed
EP-0060903-A1 A dipeptide sweetening composition and its use for sweetening food, beverages or pharmaceutical compositions AJINOMOTO CO., INC. (JP) 1982-09-29 — — EP disclosed
EP-0035047-A1 Process for the production of an alpha-L-aspartyl-L-phenylalanine lower alkyl ester and an intermediate therefor AJINOMOTO CO., INC. (JP) 1981-09-09 — — EP disclosed
EP-0035047-A1 Process for the production of an alpha-L-aspartyl-L-phenylalanine lower alkyl ester and an intermediate therefor AJINOMOTO CO., INC. (JP) 1981-09-09 — — EP disclosed
EP-0030076-A1 Purification of L-aspartyl-L-phenylalanine alkyl esters PFIZER INC. (US) 1981-06-10 — — EP disclosed
US-4173562-A ESTERIFICATION, SALT FORMATION MONSANTO COMPANY (US) 1979-11-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034460-A1 Method for preparing aspartylcyclohexyla laninamide ASNS, DNPEP, ANPEP ALDH1A1 1712/4885LMNA 1569/4885TP53 3549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.